Sciclone Pharmaceuticals
SCLN
SCLN was delisted on the 13th of October, 2017.
152 hedge funds and large institutions have $398M invested in Sciclone Pharmaceuticals in 2016 Q3 according to their latest regulatory filings, with 22 funds opening new positions, 62 increasing their positions, 46 reducing their positions, and 21 closing their positions.
54% more call options, than puts
Call options by funds: $210K | Put options by funds: $136K
35% more repeat investments, than reductions
Existing positions increased: 62 | Existing positions reduced: 46
5% more first-time investments, than exits
New positions opened: 22 | Existing positions closed: 21
1% more funds holding
Funds holding: 151 → 152 (+1)
3.58% less ownership
Funds ownership: 79.73% → 76.15% (-3.6%)
17% less capital inflows, than outflows
Capital inflows: $67.7M | Capital outflows: $81.2M
50% less funds holding in top 10
Funds holding in top 10: 2 → 1 (-1)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Numeric Investors
Boston,
Massachusetts
|
+$22.7M |
| 2 |
BlackRock Fund Advisors
San Francisco,
California
|
+$3.86M |
| 3 |
AQR Capital Management
Greenwich,
Connecticut
|
+$3.46M |
| 4 |
Dimensional Fund Advisors
Austin,
Texas
|
+$2.93M |
| 5 |
American Century Companies
Kansas City,
Missouri
|
+$2.48M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Franklin Resources
San Mateo,
California
|
-$35.4M |
| 2 |
Stonepine Capital Management
Bend,
Oregon
|
-$14.1M |
| 3 |
LSV Asset Management
Chicago,
Illinois
|
-$8.04M |
| 4 |
Invesco
Atlanta,
Georgia
|
-$5.87M |
| 5 |
Sensato Investors
San Francisco,
California
|
-$3.13M |
SCLN Hedge Fund Activity: Q3 2016 in Review
152 of the 3,759 institutional investors tracked by Wall St. Rank reported a position in Sciclone Pharmaceuticals (SCLN) for Q3 2016, worth a combined $398M — down 23% from $520M a quarter earlier.
Buyers outnumbered sellers: 22 funds opened new SCLN positions and 21 closed out — a net gain of 1 holder — while 62 added to existing stakes and 46 trimmed.
The largest buyer was Numeric Investors, adding an estimated $22.7M. The largest seller was Franklin Resources, cutting an estimated $35.4M.
- 152 institutional investors held Sciclone Pharmaceuticals (SCLN) as of Q3 2016, up from 151 in Q2 2016.
- Funds reported $398M of Sciclone Pharmaceuticals stock for Q3 2016, down 23% quarter-over-quarter.
- 22 funds opened new Sciclone Pharmaceuticals positions in Q3 2016 and 21 closed out, a net change of +1 holder.
- The largest Sciclone Pharmaceuticals buyer in Q3 2016 was Numeric Investors, an estimated $22.7M added.
- The largest Sciclone Pharmaceuticals seller in Q3 2016 was Franklin Resources, an estimated $35.4M sold.
Based on aggregated 13F filings for Q3 2016.